I'm Rebecca Friend, the new publisher of FierceMarkets' Life Sciences group. I've been with the Life Sciences group for the past two years focusing primarily in the pharma industry, and now I am looking forward to expanding my role across the entire Life Sciences network of publications.
FierceBiotech has covered its share of stories on money scandals and drug development, but this is a tempest in a proverbial tea pot.
After a slight lull in the biotech IPO arena, new offerings came barreling back this week with some fresh breakouts. In particular Foundation Medicine priced over the range and immediately soared more than 80%. And Ophthotech also crested its range, erasing any lingering doubts about the short-term sustainability of the biotech IPO frenzy. Together they raised $273 million in a 24-hour pop. Read the report >>
Biotech companies in the U.S. drew a weak $852 million in venture support over the past quarter, a distinct downturn over a burst of new financing rounds in the second quarter. That dollar figure represented a 39% plunge from the second quarter, though the smaller bankroll was divided among 123 deals, with a 10% jump in the number of companies involved.
Now available for download on the App Store for iPhone and iPad.
When John Reed headed up Sanford-Burnham Medical Research Institute, the marathon runner was well known for early starts and fast finishes. And now, as the new head of Roche's Basel-based Pharma Research and Early Development group--better known as pRED--he's in for the run of his life. Read the full feature >>
The promising early results on AstraZeneca's lung cancer drug AZD9291 won't convince anyone that the troubled company is on the turnaround trail, but it's a step in the right direction in what CEO Pascal Soriot promises will be a slow but steady reversal of its misfortunes.
The term "Big Data" sounds mostly like marketing speak to real data scientists, who work with datasets of all sizes to develop applications in healthcare and other sectors. For these data pros, it's about having the right data, not just a lot of data, to make sure they are providing something of value to a customer. Secure a seat now.
Even as some biotechs with no human data at all were being feted on Wall Street with over-the-top IPOs, the Phase IIb-proud Regado wound up having to slash its share price from a projected range of $14 to $16 a share to a mere $4.